Literature DB >> 10523297

The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity.

G Kauselmann1, M Weiler, P Wulff, S Jessberger, U Konietzko, J Scafidi, U Staubli, J Bereiter-Hahn, K Strebhardt, D Kuhl.   

Abstract

In order to stabilize changes in synaptic strength, neurons activate a program of gene expression that results in alterations of their molecular composition and structure. Here we demonstrate that Fnk and Snk, two members of the polo family of cell cycle associated kinases, are co-opted by the brain to serve in this program. Stimuli that produce synaptic plasticity, including those that evoke long-term potentiation (LTP), dramatically increase levels of both kinase mRNAs. Induced Fnk and Snk proteins are targeted to the dendrites of activated neurons, suggesting that they mediate phosphorylation of proteins in this compartment. Moreover, a conserved C-terminal domain in these kinases is shown to interact specifically with Cib, a Ca(2+)- and integrin-binding protein. Together, these studies suggest a novel signal transduction mechanism in the stabilization of long-term synaptic plasticity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523297      PMCID: PMC1171621          DOI: 10.1093/emboj/18.20.5528

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  69 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

Review 2.  Molecular mechanisms of homeostatic synaptic downscaling.

Authors:  Benjamin Siddoway; Hailong Hou; Houhui Xia
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

3.  Silencing synuclein at the synapse with PLK2.

Authors:  Brendan D Looyenga; Patrik Brundin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-26       Impact factor: 11.205

4.  Identification of novel integrin binding partners for calcium and integrin binding protein 1 (CIB1): structural and thermodynamic basis of CIB1 promiscuity.

Authors:  Thomas C Freeman; Justin L Black; Holly G Bray; Onur Dagliyan; Yi I Wu; Ashutosh Tripathy; Nikolay V Dokholyan; Tina M Leisner; Leslie V Parise
Journal:  Biochemistry       Date:  2013-09-25       Impact factor: 3.162

5.  Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Authors:  Glen J Weiss; Gayle Jameson; Daniel D Von Hoff; Barbara Valsasina; Cristina Davite; Claudia Di Giulio; Francesco Fiorentini; Rachele Alzani; Patrizia Carpinelli; Alessandro Di Sanzo; Arturo Galvani; Antonella Isacchi; Ramesh K Ramanathan
Journal:  Invest New Drugs       Date:  2017-07-20       Impact factor: 3.850

6.  Role of Plk2 (Snk) in mouse development and cell proliferation.

Authors:  Sheng Ma; Jean Charron; Raymond L Erikson
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 7.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Localized sphingolipid signaling at presynaptic terminals is regulated by calcium influx and promotes recruitment of priming factors.

Authors:  Jason P Chan; Derek Sieburth
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

Review 9.  Alternative functions of core cell cycle regulators in neuronal migration, neuronal maturation, and synaptic plasticity.

Authors:  Christopher L Frank; Li-Huei Tsai
Journal:  Neuron       Date:  2009-05-14       Impact factor: 17.173

10.  Characterization of calcium- and integrin-binding protein 1 (CIB1) knockout platelets: potential compensation by CIB family members.

Authors:  Jan C Denofrio; Weiping Yuan; Brenda R Temple; Holly R Gentry; Leslie V Parise
Journal:  Thromb Haemost       Date:  2008-11       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.